ACTIVE_NOT_RECRUITING

Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This clinical trial constructs and tests a novel multinuclear metabolic magnetic resonance imaging (MRI) sequence in patients with glioma (brain tumor) that is newly diagnosed or has come back (recurrent). This trial aims to develop new diagnostic imaging technology that may bridge gaps between early detection and diagnosis, prognosis, and treatment in brain cancer.

Official Title

Simultaneous Multinuclear (Na+/H+) Metabolic MRI in Brain Tumors

Quick Facts

Study Start:2021-09-01
Study Completion:2027-09-10
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:ACTIVE_NOT_RECRUITING

Study ID

NCT05045027

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * AIM 1: Healthy volunteers with no evidence of brain tumors or neurologic disease
  2. * AIM 1: Age 18+
  3. * AIM 2: Newly diagnosed or recurrent suspected or confirmed glioma (low or high grade)
  4. * AIM 2: 10 IDH mutant and 10 IDH wild type gliomas
  5. * AIM 2: Clinically indicated for resective surgery or biopsy
  6. * AIM 2: Age 18+
  7. * AIM 2: Tumor size \> 1x1x1 cm (measurable)
  8. * AIM 3: Recurrent glioma enrolled in an immunotherapy trial or clinically indicated to receive immunotherapy including anti-PD1
  9. * AIM 3: Age 18+
  1. * AIM 1: Cannot safely perform an MRI
  2. * AIM 1: Age \< 18
  3. * AIM 2: Cannot safely perform an MRI or use of MRI contrast agents
  4. * AIM 2: Age \< 18
  5. * AIM 3: Cannot safely perform an MRI or use of MRI contrast agents
  6. * AIM 3: Age \< 18

Contacts and Locations

Principal Investigator

Benjamin M Ellingson
PRINCIPAL_INVESTIGATOR
UCLA / Jonsson Comprehensive Cancer Center

Study Locations (Sites)

UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, 90095
United States

Collaborators and Investigators

Sponsor: Jonsson Comprehensive Cancer Center

  • Benjamin M Ellingson, PRINCIPAL_INVESTIGATOR, UCLA / Jonsson Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2021-09-01
Study Completion Date2027-09-10

Study Record Updates

Study Start Date2021-09-01
Study Completion Date2027-09-10

Terms related to this study

Additional Relevant MeSH Terms

  • Glioma
  • Malignant Glioma
  • Recurrent Glioma
  • Recurrent Malignant Glioma